Monoclonal antibodies in oncology.

Monoclonal antibodies in oncology.

Monoclonal antibodies (MCAs) can be used to differentiate between normal and neoplastic cells and thus exploited for diagnostic and, ultimately, therapeutic gain. The evidence for the existence of human tumour antigens is reviewed. Several areas of diagnosis are already benefiting from the application of the monoclonal technology. Immunohistology can help the pathologist with difficult diagnost...

Therapeutic monoclonal antibodies in oncology.

Monoclonal antibodies in neuro-oncology

Monoclonal antibodies (mAbs) are used with increasing success against many tumors but, for brain tumors, the blood-brain barrier (BBB) is a special concern. The BBB prevents antibody entry to the normal brain; however, its role in brain tumor therapy is more complex. The BBB is closest to normal at micro-tumor sites; its properties and importance change as the tumor grows. In this review, evolv...

Monoclonal Antibodies

SUMMARY Monoclonal Antibodies are identical antibodies and Can be generated in ultimated amounts by countinuos cultures of single antibody- secreting cells. These cell lines are produced by cell fusion of normal lymphocytes to cells of a myeloma tumor cell line, which confers on the antibody producing hybrid cell, immortality and the ability grow as atumor in animals. monoclonal antibodies c...

The use of monoclonal antibodies in oncology.

01. In general, the administration of monoclonal antibodies in the oncology setting should be given via IV using a. Bolus push. b. Slow infusion. c. Free-flowing drip. d. Patient-controlled administration. 02. Mrs. Hoffman has been receiving alemtuzumab (Campath, Berlex Inc., Richmond, CA) 30 mg three times per week for eight weeks. Recently, she required a three-week break from her therapy bec...